Eli Lilly Net Worth

Eli Lilly Net Worth Analysis

Eli Lilly Target Price Consensus

Eli Lilly Target Price Projection

Eli Lilly's current and average target prices are 824.76 and 984.05, respectively. The current price of Eli Lilly is the price at which Eli Lilly and is currently trading. On the other hand, Eli Lilly's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Eli Lilly and and the information provided on this page.

Know Eli Lilly's Top Institutional Investors

Note, although Eli Lilly's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Eli Lilly's market capitalization trends

The company currently falls under 'Mega-Cap' category with a total capitalization of 730.64 B.

Project Eli Lilly's profitablity

The company has Net Profit Margin of 0.24 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.43 %, which entails that for every 100 dollars of revenue, it generated $0.43 of operating income.

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Evaluate Eli Lilly's management efficiency

Eli Lilly has Return on Asset of 0.1533 % which means that on every $100 spent on assets, it made $0.1533 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.8426 %, implying that it generated $0.8426 on every 100 dollars invested. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.78 in 2025, whereas Return On Tangible Assets are likely to drop 0.14 in 2025. At this time, Eli Lilly's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 48.3 B in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 3 B in 2025.

Eli Lilly Corporate Filings

Eli Lilly time-series forecasting models is one of many Eli Lilly's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Eli Lilly's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Eli Lilly Earnings Estimation Breakdown

The calculation of Eli Lilly's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Eli Lilly is estimated to be 4.6911 with the future projection ranging from a low of 4.2 to a high of 5.36. Please be aware that this consensus of annual earnings estimates for Eli Lilly and is based on EPS before non-recurring items and includes expenses related to employee stock options.

Eli Lilly Earnings Projection Consensus

Eli Lilly Earnings History

Earnings estimate consensus by Eli Lilly analysts from Wall Street is used by the market to judge Eli Lilly's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Eli Lilly's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods. Price Earnings Ratio is likely to rise to 68.70 in 2025, whereas Retained Earnings are likely to drop slightly above 9.6 B in 2025. Common Stock Shares Outstanding is likely to drop to about 864.7 M in 2025. Net Income Applicable To Common Shares is likely to drop to about 4 B in 2025.

Hype Prediction Low Estimated High 811.19 813.20 815.21 Details

Intrinsic Valuation Low Real High 782.87 784.88 894.83 Details

Naive Forecast Low Next High 766.42 768.43 770.45 Details

28 Analysts Consensus Low Target High 895.48 984.05 1,092 Details

Note that many institutional investors and large investment bankers can move markets due to the volume of Eli assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Eli Lilly. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Eli Lilly's stock price in the short term.

Eli Lilly Earnings per Share Projection vs Actual

Actual Earning per Share of Eli Lilly refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Eli Lilly and predict the company's earnings will be in the future. The higher the earnings per share of Eli Lilly, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Eli Lilly Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Eli Lilly, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Eli Lilly should always be considered in relation to other companies to make a more educated investment decision.

Eli Quarterly Analyst Estimates and Surprise Metrics

Eli Lilly Corporate Directors

Additional Tools for Eli Stock Analysis